Indication
HER2-positive Advanced Solid Tumors
3 clinical trials
4 products
Product
TebotelimabClinical trial
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein Binding PD-1 and LAG-3 in Patients With Unresectable or Metastatic NeoplasmsStatus: Completed, Estimated PCD: 2023-02-08
Product
margetuximabClinical trial
A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of SPH5030 Tablets in Subjects With Advanced Her2-positive Solid TumorsStatus: Recruiting, Estimated PCD: 2024-06-21
Product
SPH5030Clinical trial
A Multi-center, Single-arm, Phase І Study of DP303c in Patients With HER2-positive Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2023-12-23
Product
DP303c